Adjuvant Chemoimmunotherapy After Regional Lymphadenectomy for Malignant Melanoma

Ea, Abdi; Hanson, John; Ta, McPherson

doi:10.1097/00000421-198704000-00044

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other words, why does the subject need a special statistical theory [1,2]? The answer is given in section on "Special Features of Survival Data" [3,4]. We also try to answer some other questions:…”

Section: Introductionmentioning

confidence: 99%

Statistics for Surgeons – Understanding Survival Analysis

Agarwal

2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Survival data stand out as a special statistical field. This paper tries to describe what survival data is and what makes it so special. Survival data concerns times to some events. A key point is the successive observation of time, which on the one hand leads to sometimes not being observed so that all that is known is that they exceed some given times (censoring), and on the other hand implies that predictions regarding the future course should be conditional on the present status (truncation). In the simplest case, this condition is that the individual is alive. The successive conditioning makes the hazard function, which describes the probability of an event happening during a short interval given that the individual is alive today, the most relevant concept. Here we discuss parametric as well as non-parametric methods. Examples are presented in a way that can be followed without the help of computers.

show abstract

Section: Introductionmentioning

confidence: 99%

Statistics for Surgeons – Understanding Survival Analysis

Agarwal

2012

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Nevertheless chemotherapy has been reported by Gutterman ct al. [21] as effective when combined with BCG while others have failed to con firm these results [4,22,23].…”

Section: Introductionmentioning

confidence: 99%

Adjuvant Treatment in Stage I and II Malignant Melanoma: A Randomized Trial between Chemoimmunotherapy and Immunotherapy

Castel¹,

Vila²,

Viñolas³

et al. 1991

Dermatology

View full text Add to dashboard Cite

A randomized trial comparing chemoimmunotherapy (bacillus Calmette-Guérin + chemotherapy) and immunotherapy (bacillus Calmette-Guérin alone) was carried out in high-risk stage I and II malignant melanoma patients. Eighty-two evaluable patients were included. The follow-up median duration was 11 years. Recurrent melanoma developed in 28 patients (34%). The overall survival rate was 76% at 5 years and 65% at 10 years. There were no statistical differences in survival probability or disease-free survival (DFS) probability between the two treatment groups. Survival and DFS were also analyzed in relation to various prognostic factors. Statistically significant differences were only seen in a subset of 33 patients with lower limb malignant melanoma, the prognosis being better for the chemoimmunotherapy group in this location. Because of the small number of patients in each group, a week positive effect of either of these two treatments cannot be ruled out. Chemoimmunotherapy only seems to improve the prognosis of stage I or II malignant melanoma of the legs.

show abstract